Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sophie C Prendergast"'
Publikováno v:
IJU Case Reports, Vol 6, Iss 6, Pp 373-376 (2023)
Introduction Large cell calcifying Sertoli cell tumors are exceedingly rare. They are most commonly benign, but risks for malignancy include older age, larger size of tumor, and solitary tumors. To the author's knowledge, this is the first case repor
Externí odkaz:
https://doaj.org/article/69f68cdf439c4501a8cd21c060da1451
Autor:
Sophie C Prendergast, Anna‐Christina Strobl, William Cross, Nischalan Pillay, Sandra J Strauss, Hongtao Ye, Daniel Lindsay, Roberto Tirabosco, Jane Chalker, Shazia S Mahamdallie, Alona Sosinsky, RNOH Pathology Laboratory and Biobank Team, Genomics England Research Consortium, Adrienne M Flanagan, Fernanda Amary
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 6, Iss 4, Pp 297-307 (2020)
Abstract The largest whole genome sequencing (WGS) endeavour involving cancer and rare diseases was initiated in the UK in 2015 and ran for 5 years. Despite its rarity, sarcoma ranked third overall among the number of patients' samples sent for seque
Externí odkaz:
https://doaj.org/article/c5fa0f3501e045e8bd224bb48174ec81
Publikováno v:
European Journal of Case Reports in Internal Medicine (2024)
Case description: We describe a case of a patient treated with pembrolizumab (an immune checkpoint inhibitor) for metastatic scalp melanoma. He had a previous history of colorectal cancer, prostatic cancer and chronic polymyalgia rheumatica. The pati
Externí odkaz:
https://doaj.org/article/9f78f7a28abc49ed9a52ec32c384629b
Autor:
Adrienne M. Flanagan, Sophie C Prendergast, Nischalan Pillay, Alona Sosinsky, Hongtao Ye, Shazia Mahamdallie, Biobank Team, Daniel Lindsay, Roberto Tirabosco, Jane Chalker, Fernanda Amary, William Cross, Anna-Christina Strobl, Sandra J. Strauss
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 6, Iss 4, Pp 297-307 (2020)
The Journal of Pathology: Clinical Research
The Journal of Pathology: Clinical Research
The largest whole genome sequencing (WGS) endeavour involving cancer and rare diseases was initiated in the UK in 2015 and ran for 5 years. Despite its rarity, sarcoma ranked third overall among the number of patients' samples sent for sequencing. He